CytoSorbents Showcases Blood Purification Innovations at Jefferies Global Healthcare Conference
- CytoSorbents will showcase its blood purification technologies at the Jefferies Global Healthcare Conference in November 2025.
- The flagship product, CytoSorb®, effectively removes harmful substances from blood during critical care procedures.
- CytoSorbents has distributed nearly 300,000 CytoSorb® devices across over 70 countries, enhancing patient outcomes in critical care.
CytoSorbents Advances Blood Purification Technologies at Upcoming Healthcare Conference
CytoSorbents Corporation, a leader in the field of blood purification, prepares to showcase its innovative solutions at the Jefferies Global Healthcare Conference in London from November 17-20, 2025. The company is set to present on November 18, 2025, at 12:30 PM GMT (7:30 AM ET), with a live webcast available on their official website. This engagement marks a significant opportunity for CytoSorbents to highlight its proprietary technologies and their impact on critical care, particularly in intensive care settings and cardiac surgery.
At the core of CytoSorbents' advancements is its flagship product, CytoSorb®, which employs biocompatible, porous polymer beads designed to effectively remove harmful substances from blood and bodily fluids. The technology works by integrating with existing hospital blood pumps, such as dialysis and ECMO machines, allowing for the safe recirculation of blood while eliminating toxic agents. This functionality is vital in managing life-threatening conditions, including the removal of blood thinners during cardiothoracic surgeries to reduce bleeding risks and filtering inflammatory agents in severe cases of sepsis, trauma, and liver failure. Such interventions are critical in preventing organ failure and improving patient survival rates.
CytoSorbents has established a notable presence in the medical market, with its products CE-marked and distributed across over 70 countries. To date, nearly 300,000 CytoSorb® devices have been utilized, underscoring its role as the first cytokine adsorber available in the European Union. The company’s commitment to innovation in blood purification technologies not only addresses immediate health challenges but also enhances overall patient outcomes in critical care environments, where treatment options can be sparse. Through their participation in the healthcare conference, CytoSorbents aims to strengthen its position as a key player in the medical field and draw attention to the life-saving potential of its technologies.
In addition to its conference participation, CytoSorbents continues to engage with the medical community and stakeholders to emphasize the importance of its blood purification technologies. The company’s focus on addressing critical health issues through innovative solutions highlights the ongoing need for advancements in intensive care treatments. As the healthcare landscape evolves, CytoSorbents remains committed to enhancing patient care and outcomes through its pioneering approaches in blood purification.